logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9107862 B1

PDFFull Text
Date of Patent:
Aug. 18, 2015

Filed:

Feb. 15, 2013

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

Applicant:

Compugen Ltd., Tel Aviv-Jaffa, IL;

Inventors:

Amir Toporik, Holon, IL;

Amit Novik, Binyamina, IL;

Anat Cohen-Dayag, Rehovot, IL;

Avi Yeshah Rosenberg, Kfar Saba, IL;

Cynthia Koifman, Kfar-Saba, IL;

Dalit Landesman-Milo, Ramat Gan, IL;

Eve Montia, Rehovot, IL;

Galit Rotman, Herzliyya, IL;

Liat Dassa, Yehud, IL;

Marina Bubis, Rehovot, IL;

Merav Beiman, Nes Ziona, IL;

Ofer Levy, Moshav Mesisraelat Zion, IL;

Sergey Nemzer, Ra'ananna, IL;

Tania Pergam, Rishon Le Zion, IL;

Yaron Kinar, Tel Aviv-Jaffa, IL;

Shirley Sameach-Greenwald, Kfar-Saba, IL;

Zurit Levine, Herzliyya, IL;

Shira Walach, Hod Hasharon, IL;

Assignee:

Compugen Ltd., Tel Aviv, IL;

Attorneys:

Graeser Associates International Inc

Dvorah Graeser

Primary Examiner:

Ilia Ouspenski

Int. Cl.
CPC ...
C07K 14/00 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); G01N 33/564 (2006.01); G01N 33/574 (2006.01); A61K 31/7088 (2006.01); C07K 14/47 (2006.01); C07K 14/82 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/39 (2006.01); A61K 47/48 (2006.01); A61N 5/10 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0008 (2013.01); A61K 31/7088 (2013.01); A61K 39/00 (2013.01); A61K 39/0005 (2013.01); A61K 39/39 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/48569 (2013.01); A61N 5/10 (2013.01); C07K 14/00 (2013.01); C07K 14/47 (2013.01); C07K 14/4702 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/82 (2013.01); C07K 16/28 (2013.01); C07K 16/30 (2013.01); G01N 33/564 (2013.01); G01N 33/57419 (2013.01); G01N 33/57423 (2013.01); G01N 33/57449 (2013.01); G01N 33/57484 (2013.01); G01N 33/57492 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/60 (2013.01); C07K 2319/70 (2013.01); G01N 2500/04 (2013.01);
Abstract

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

Find Patent Forward Citations

Loading…